TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zelira Therapeutics ( (AU:ZLD) ) has shared an announcement.
Zelira Therapeutics has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to ASX Corporate Governance Council’s principles, detailing the roles and responsibilities of the board and management, and the processes for director appointments and accountability, thereby reinforcing its commitment to transparency and effective governance practices.
The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
More about Zelira Therapeutics
Zelira Therapeutics Limited operates in the biotechnology industry, focusing on the development and commercialization of cannabinoid-based medicines. The company targets various therapeutic areas, including pain management and sleep disorders, leveraging its expertise in cannabinoid formulations to address unmet medical needs.
Average Trading Volume: 2,781
Technical Sentiment Signal: Sell
Current Market Cap: A$5M
See more insights into ZLD stock on TipRanks’ Stock Analysis page.